Patrick Campbell

A study from ESC 2019 found the occurrence of ACS was more common in winter months and heavily polluted cities after examining more than 15,000 patients from across Poland.

Results of the PolyIran study, which examined more than 6000 patients, found that use of a polypill reduced the risk of major cardiovascular events.

National Institute of Health Research study found that physicial activity, even for just 24 minutes per day, was associated with reduced risk of all-cause mortality.

World Health Organization review finds that consumption of fish oil supplements have little to no impact on development or diagnosis of diabetes.

A recent analysis of the Asian Sudden Cardiac Death in Heart Failure registry found that type 2 diabetes mellitus was associated with structural changes of the heart and poorer quality of life.

Findings from the Insight 46 study reveal blood pressure changes during midlife can lead to poorer brain health as a patient gets older.

Analysis of the Framingham Heart Study found that while quitting smoking lowers a person's CVD risk, that risk may not return to normal for up to 25 years.

Investigators from the University of Pennsylvania found that negative effects of vaping on blood vessels can be noted after a single use.

FDA announced the approval of lefamulin, which was based on the results of the LEAP 1 and LEAP 2 trials.

While many often turn to vitamins and nutritional supplements for nutrients their diet lacks, some argue this is not enough to make up for the missing nutrients.

Despite potentially playing a key role in the lives of patients, little is known about the true impact of gut microbiota on metabolic health. Hana Kahleova, MD, PhD, discusses the reality of our understanding in a recent interview.

While results of COMPASS proved the efficacy of combination rivaroxban-plus-aspirin, it may not be the best treatment for every patient suffering from coronary or peripheral artery disease.

After showing a significant impact on reduction of cardiovascular events, a slew of subgroup analyses were performed examining use of icosapent ethyl using data derived from REDUCE-IT.

Trial investigator Deepak Bhatt, MD, MPH, discusses how use of rivaroxaban in a clinical setting has changed as a result of the COMPASS trial.

Lead investigator of REDUCE-IT trials discusses the impact of trial results and what that means for EPA-based treatments going forward.

Use of rivaroxaban (Xarelto) plus aspirin was found to reduce cardiovascular and major limb events in a secondary analysis of the COMPASS trial.

OSA patients with certain traits experienced a 73% reduction in AHI events from oral appliance treatment.

A recent study examining the effectiveness of an offline, automated smartphone-based AI system could be giving physicians a glimpse into the future of eye screening.

Drinking more than 3 servings of caffeinated beverages per day was associated with an increase in migraine headaches.

Individuals with increased levels of inflammation after 1 year were associated higher rates of all-cause mortality and mortality attributable to cardiovascular disease and cancer.

Strict adherence to a plant-based diet could result in a 16% reduction in risk of having a cardiovascular disease.

A 24-week randomized clinical trial found PRT-P led to improvements in social communication skills among children with ASD.

AbbVie's submitted NDA for elagolix for the treatment of heavy menstrual bleeding associated with uterine fibroids in women is supported by the results of 2 phase 3 studies.

Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant associated with low rates of major bleeding and arterial thromboembolism in the PAUSE study.

Obesity, smoking, and other trends are slowing the rate of decline, and even causing increases, of cardiovascular disease in many high-income countries across the world.

Deepak Bhatt, MD, discusses the results of the COMPASS trial and how they have impacted clinical practice.

Steven Edelman, MD, clinical professor of medicine at UC San Diego, discusses glucose control among pediatric patients after a trial into the efficacy of inhaled insulin opened enrollment earlier this week.

A study presented at ASRS 2019 found that the ranibizumab biosimilar (razumab) was noninferior to ranibizumab after 1 month of treatment.

A former D.C. healthcare attorney and founder of the Macular Degeneration Association discusses legal problems faced by retina specialists when providing care to their patients with AMD.

Chirag Jhaveri, MD, took part in a Q&A about the results of the phase 3 HAWK and HARRIER studies examining brolucizumab for treatment of nAMD.